Semaglutide leads to greater weight loss in women than men with HF, improves HF symptoms in both sexes

An update in the STEP-HfpEF Program study gives key insights into sex differences and semaglutide

2024-06-23

(Press-News.org) Key Findings:

Weight Loss: Women lost 9.6% of their body weight on average with semaglutide, compared with 7.2% in men, marking a significant difference. Symptom Improvement: Both sexes saw notable improvements in HF symptoms, physical limitations, and exercise function. Heart Failure Benefits Beyond Weight Loss: Despite greater weight loss in women, the improvement in HF symptoms was similar between sexes, suggesting semaglutide's heart failure benefits may be, in part, independent of weight loss. WASHINGTON (June 23, 2024) – Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. Women experienced greater weight loss and the same symptom benefits compared with men, according to research presented today by Dr. Subodh Verma (St. Michael’s Hospital, University of Toronto) at the American Diabetes Association’s 2024 Scientific Sessions and published in the Journal of the American College of Cardiology (JACC).

This secondary analysis of the STEP-HFpEF (Semaglutide Treatment Effect in People with Obesity and HFpEF) program reveals that semaglutide provides benefits for men and women that do not track directly with weight loss, suggesting the drug may also have weight-loss independent effects on the cardiovascular system. The study (which included two trials) compared semaglutide with a placebo over 52 weeks in 1,145 participants, highlighting intriguing sex differences.

The analysis sought to determine whether phenotypic features and treatment effects of semaglutide vary by sex in obesity-related heart failure (HF) with preserved ejection fraction (HFpEF). It evaluated the influence of sex on the disease’s baseline characteristics and compared the effects of semaglutide versus placebo on key trial endpoints in the STEP-HFpEF program (comprised of STEP-HFpEF and STEP-HFpEF DM Trials).

“Understanding the sex differences in obesity-related HFpEF is of great importance. Obesity and visceral adiposity are key drivers of HFpEF development and progression, and this may be even more amplified in women, who represent the majority of people with the disease, and bear a heavier burden of symptoms and physical limitations due to HFpEF” said Mikhail Kosiborod, MD, FACC, senior author of the study and a cardiologist at Saint Luke's Mid-America Heart Institute in Kansas City, Missouri. “Our study sheds light on these differences and the consistent benefits of semaglutide for women and men.”

Lead author, Dr. Subodh Verma commented that “women living with obesity and heart failure with a preserved ejection fraction were also found to have higher BMI’s compared to men, and were much more symptomatic at baseline.”

“Females had more systemic inflammation and compared to previous HfpEF studies, females with obesity-related HfpEF were also younger,” Verma said.

The study analyzed the effects of semaglutide 2.4 mg administered to participants once weekly vs placebo on the STEP-HFpEF program’s dual primary and confirmatory secondary, and exploratory outcomes by sex. A total of 1,145 participants with obesity-related HFpEF were evaluated over 52 weeks, of which 570 were females.

Semaglutide, compared with placebo, similarly improved HF-related symptoms, physical limitations, exercise function, and reduced inflammation and natriuretic peptides regardless of sex.

Semaglutide-mediated improvements in HF-related symptoms and physical limitations were consistent in both male and female participants across key subgroups including age and BMI. It also lowered their systolic blood pressure and waist circumference.

However, there were sex differences in the treatment effects in terms of the reduction in body weight with semaglutide. Female participants experienced greater weight loss than males, with a mean difference of -9.6% vs -7.2%. Even though there was a significant reduction in body weight in both sexes, it was greater in females (a statistically significant interaction).

At baseline, females had higher left ventricular ejection fraction, presented with worse symptoms and physical limitations, and had higher levels of inflammation at baseline, but similar rates of hypertension and diuretic use and less atrial fibrillation compared with males, despite their higher BMI. Researchers note that this may indicate that more female participants had a typical obesity phenotype of HFpEF compared with males who may also have left atrial myopathy HFpEF complicated by an increase in BMI.

In an accompanying editorial, Anuradha Lala, MD, a cardiologist at the Mount Sinai School of Medicine and Director of Heart Failure Research for the NHLBI Cardiothoracic Surgery Network, said there is a need for further studies to illuminate the mechanism by which this drug provides benefits and continued attention to sex-specific differences in treatment responses.

The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all. As the preeminent source of professional medical education for the entire cardiovascular care team since 1949, ACC credentials cardiovascular professionals in over 140 countries who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. Through its world-renowned family of JACC Journals, NCDR registries, ACC Accreditation Services, global network of Member Sections, CardioSmart patient resources and more, the College is committed to ensuring a world where science, knowledge and innovation optimize patient care and outcomes. Learn more at www.ACC.org or follow @ACCinTouch.

The ACC’s JACC Journals rank among the top cardiovascular journals in the world for scientific impact. The flagship journal, the Journal of the American College of Cardiology (JACC) — and specialty journals consisting of JACC: Advances, JACC: Asia, JACC: Basic to Translational Science, JACC: CardioOncology, JACC: Cardiovascular Imaging, JACC: Cardiovascular Interventions, JACC: Case Reports, JACC: Clinical Electrophysiology and JACC: Heart Failure — pride themselves on publishing the top peer-reviewed research on all aspects of cardiovascular disease. Learn more at JACC.org.

###

END

ELSE PRESS RELEASES FROM THIS DATE:

12.5, the 1st Impact Factor of COMMTR released!

2024-06-22

Clarivate released the first Impact Factor (2023 IF) of Communications in Transportation Research (COMMTR) on June 20, 2024. COMMTR's 2023 IF is 12.5, ranking in Top 1 (1/57, Q1) among all journals in "TRANSPORTATION" category, and its 2023 CiteScore is 15.2 (top 5%) in Scopus database. We would like to express our sincere appreciation for the authors, reviewers, readers, editorial board members for helping to make the journal a success. We welcome your continued readership and article ...

Circadian clock impact on cluster headaches funded by $2.4M NIH grant for UTHealth Houston research

2024-06-21

The link between severe headache disorders headaches and the body’s circadian clock in pain timing and thresholds will be studied with a $2.4 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) to UTHealth Houston researchers. The research is led by two faculty members of McGovern Medical School at UTHealth Houston: Mark Burish, MD, PhD, associate professor in the Vivian L. Smith Department of Neurosurgery, and Seung-Hee Yoo, PhD, associate professor in the Department of Biochemistry and Molecular Biology. The study builds on earlier research by Burish and Yoo, funded by the Will Erwin Headache Research Foundation and published ...

Study identifies first drug therapy for sleep apnea

2024-06-21

Researchers at University of California San Diego School of Medicine and international collaborators have led a worldwide, advanced study demonstrating the potential of tirzepatide, known to manage type 2 diabetes, as the first effective drug therapy for obstructive sleep apnea (OSA), a sleep-related disorder characterized by repeated episodes of irregular breathing due to complete or partial blockage of the upper airway. The results, published in the June 21, 2024 online edition of New England Journal of Medicine, highlight the treatment’s potential to improve the quality of life for millions around the world affected by OSA. “This study marks a significant ...

How old is your bone marrow?

2024-06-21

Our bone marrow—the fatty, jelly-like substance inside our bones—is an unseen powerhouse quietly producing 500 billion new blood cells every day. That process is driven by hematopoietic stem cells that generate all of the various types of blood cells in our bodies and regenerating themselves to keep the entire assembly line of blood production operating smoothly. As with any complex system, hematopoietic stem cells lose functionality as they age—and, in the process, contribute to the risk of serious diseases, including blood cancers. We know that the risk of developing aging-associated diseases is different among different individuals. ...

Boosting biodiversity without hurting local economies

2024-06-21

DURHAM, N.C. -- Protected areas, like nature reserves, can conserve biodiversity without harming local economic growth, countering a common belief that conservation restricts development. A new study outlines what is needed for conservation to benefit both nature and people. Conservation zones aim to preserve biodiversity, protect endangered species, and maintain natural habitats. “There’s long been uncertainty about the economic tradeoffs,” said Binbin Li, associate professor of environmental science at Duke Kunshan University, and lead author ...

ChatGPT is biased against resumes with credentials that imply a disability — but it can improve

2024-06-21

While seeking research internships last year, University of Washington graduate student Kate Glazko noticed recruiters posting online that they’d used OpenAI’s ChatGPT and other artificial intelligence tools to summarize resumes and rank candidates. Automated screening has been commonplace in hiring for decades. Yet Glazko, a doctoral student in the UW’s Paul G. Allen School of Computer Science & Engineering, studies how generative AI can replicate and amplify real-world biases — such as those against disabled people. How might such a system, she wondered, rank resumes that implied someone had a disability? In ...

Simple test for flu could improve diagnosis and surveillance

2024-06-21

Fewer than one percent of people who get the flu every year get tested, in part because most tests require trained personnel and expensive equipment. Now researchers have developed a low-cost paper strip test that could allow more patients to find out which type of flu they have and get the right treatment. The test, developed by a team from the Broad Institute of MIT and Harvard and Princeton University, and supported by the US Centers for Disease Control and Prevention, uses CRISPR to distinguish between the two main types of seasonal flu, influenza A and B, as well as seasonal ...

UT Health San Antonio researcher awarded five-year, $2.53 million NIH grant to study alcohol-assisted liver disease

2024-06-21

SAN ANTONIO, June 21, 2024 – Liver transplants associated with alcohol-related disease are growing at a rapid pace, shifting research to address pathologies behind the ailments in light of a limited supply of organ donors. At the forefront is Mengwei Zang, MD, PhD, an internationally recognized leader in chronic liver disease research at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) who was just awarded a groundbreaking five-year, $2.53 million grant from the National ...

Giving pre-med students hands-on clinical training

2024-06-21

A group of pre-medical students received valuable hands-on clinical training during a workshop in the new Smart Hospital at The University of Texas at Arlington. The Clinical Experience Workshop allowed 10 pre-med students to participate in experiential activities and to interact one-on-one with “patients” portrayed by students from the UTA Department of Theatre Arts. “This was a clinical opportunity for pre-med students with no clinical background to be immersed in clinical medicine, learn basic skills, and experience actual patient encounters with simulated patients ...

CAMH research suggests potential targets for prevention and early identification of psychotic disorders

2024-06-21

A new study by the Centre for Addiction and Mental Health (CAMH), entitled Mental Health Service Use Before First Diagnosis of a Psychotic Disorder and published in JAMA Psychiatry, found that nearly 75 per cent of young Ontarians with a psychotic disorder had at least one mental health service visit within the three years prior to their first diagnosis of the disorder. The retrospective cohort study—one of the largest of its kind—suggests that youth with a psychotic disorder are nearly four times as likely to have a previous mental health-related hospital ...